Cadrenal Therapeutics, Inc. CVKD 深 滬
等待開盤 08-13 09:30:00 美东时间
10.9227
-0.017
-0.16%
華盛通- 最 高11.00
- 今 開11.00
- 成交量 1.13万股
- 最 低 10.5513
- 昨 收 10.94
- 總市值 2148.17万
- 52周最高 22.9011
- 市盈率 靜 --
- 換手率 0.58%
- 52周最低 6.89
- 委 比 95.12%
- 總股本 196.67万
- 歷史最高 101.25
- 量 比 0.37
- 振 幅 4.10%
- 歷史最低 5.40
- 每 手 1
- 風險率 3.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cadrenal Therapeutics GAAP EPS of -$1.87
Cadrenal Therapeutics press release (NASDAQ:CVKD): Q2 GAAP EPS of -$1.87. On June 30, 2025, Cadrenal had cash and cash equivalents of $5.6 million, compared to $10.0 million as of December 31, 2024. T...
08-12 02:08
Cadrenal Therapeutics Q2 EPS $(1.87) Misses $(1.60) Estimate
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.87) per share which missed the analyst consensus estimate of $(1.60) by 17.09 percent. This is a 16.89 percent increase over losses of $(2.25) per
08-11 20:12
Cadrenal Therapeutics shares are trading higher after the company announced clinical trial initiation plans for its lead late-stage drug candidate, tecarfarin, in patients with ESKD who are transitioning to dialysis.
Cadrenal Therapeutics shares are trading higher after the company announced cli...
08-05 23:09
Cadrenal Therapeutics Director Resignation Announced
Cadrenal Therapeutics, Inc. ( ($CVKD) ) just unveiled an announcement. On July ...
07-19 05:19
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 239.4% to $17.55 dur...
07-14 20:08
Cadrenal Therapeutics Highlights Tecarfarin As Safer Anticoagulant Alternative For High-Risk LVAD Patients
LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as strokeHospitalization costs for patients following a major bleeding
06-12 20:18
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
Cadrenal Therapeutics Announces Manufacturing And Supply Chain Milestones For Tecarfarin, Oral VKA Anticoagulant Designed To Address Unmet Needs In Anticoagulation Therapy
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug
05-15 19:35
Cadrenal Therapeutics Q1 EPS $(2.09) Misses $(1.25) Estimate
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(2.09) per share which missed the analyst consensus estimate of $(1.25) by 67.2 percent. This is a 39.33 percent decrease over losses of $(1.50) per share
05-08 20:13
Noble Financial Remains a Buy on Cadrenal Therapeutics, Inc. (CVKD)
Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Cadrenal Ther...
03-14 21:35
